Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers

Journal of the American Academy of Dermatology

Volumn 68, Issue 2, 2013, Pages 284-289

  Solomon, Michal ^a   Pavlotzky, Felix ^a   Barzilai, Aviv ^a   Schwartz, Eli ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Bolivia; L (V) braziliensis; liposomal amphotericin B (L AmB); sodium stibogluconate; travelers

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; STIBOGLUCONATE SODIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LEISHMANIA BRAZILIENSIS; MALE; NEPHROTOXICITY; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN LEISHMANIASIS; THERAPY EFFECT; TRAVEL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AMPHOTERICIN B; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; BOLIVIA; FEMALE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; ISRAEL; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MALE; TREATMENT OUTCOME;

EID: 84872322519     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.06.014     Document Type: Article

References (21)

1. E. Schwartz, C. Hatz, and J. Blum New world cutaneous leishmaniasis in travellers Lancet Infect Dis 6 2006 342 349
2. B.L. Herwaldt Leishmaniasis Lancet 354 1999 1191 1199
3. A. Scope, H. Trau, G. Anders, A. Barzilai, Y. Confino, and E. Schwartz Experience with New World cutaneous leishmaniasis in travelers J Am Acad Dermatol 49 2003 672 678
4. B.L. Herwaldt, and J.D. Berman Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies Am J Trop Med Hyg 46 1992 296 306
5. S.D. Lawn, M. Armstrong, D. Chilton, and C.J. Whitty Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers Trans R Soc Trop Med Hyg 100 2006 264 269
6. A. Llanos-Cuentas, G. Tulliano, R. Araujo-Castillo, C. Miranda-Verastegui, G. Santamaria-Castrellon, and L. Ramirez Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru Clin Infect Dis 46 2008 223 231
7. F.F. Tuon, V.S. Amato, M.E. Graf, A.M. Siqueira, A.C. Nicodemo, and V. Amato Neto Treatment of New World cutaneous leishmaniasis - a systematic review with a meta-Analysis Int J Dermatol 47 2008 109 124
8. V.S. Amato, A. Rabello, A. Rotondo-Silva, A. Kono, T.P. Maldonado, and I.C. Alves Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients Acta Trop 92 2004 127 132
9. M. Brown, M. Noursadeghi, J. Boyle, and R.N. Davidson Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis Br J Dermatol 153 2005 203 205
10. T. del Rosal, F.B. Artigao, M.J. Miguel, R. de Lucas, and F. del Castillo Successful treatment of childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases J Trop Pediatr 56 2010 122 124
11. A. Perez-Ayala, F. Norman, J.A. Perez-Molina, J.M. Herrero, B. Monge, and R. Lopez-Velez Imported leishmaniasis: a heterogeneous group of diseases J Travel Med 16 2009 395 401
12. R. Ramanathan, K.R. Talaat, D.P. Fedorko, S. Mahanty, and T.E. Nash A species-specific approach to the use of non-Antimony treatments for cutaneous leishmaniasis Am J Trop Med Hyg 84 2011 109 117
13. G. Wortmann, M. Zapor, R. Ressner, S. Fraser, J. Hartzell, and J. Pierson Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis Am J Trop Med Hyg 83 2010 1028 1033
14. M. Solomon, S. Baum, A. Barzilai, A. Scope, H. Trau, and E. Schwartz Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis J Am Acad Dermatol 56 2007 612 616
15. G. Schonian, A. Nasereddin, N. Dinse, C. Schweynoch, H.D. Schallig, and W. Presber PCR diagnosis and characterization of Leishmania in local and imported clinical samples Diagn Microbiol Infect Dis 47 2003 349 358
16. N.E. Aronson, G.W. Wortmann, S.C. Johnson, J.E. Jackson, R.A. Gasser Jr., and A.J. Magill Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience Clin Infect Dis 27 1998 1457 1464
17. L. El Hajj, M. Thellier, J. Carriere, F. Bricaire, M. Danis, and E. Caumes Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases Int J Dermatol 43 2004 120 125
18. J. Blum, P. Desjeux, E. Schwartz, B. Beck, and C. Hatz Treatment of cutaneous leishmaniasis among travellers J Antimicrob Chemother 53 2004 158 166
19. J. Motta, and R. Sampaio A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis J Eur Acad Dermatol Venereol 26 2012 331 335 Epub 2011 Apr 15
20. R.K. Devlin, J. Parsonnet, and S.N. Klaus Treatment of relapsed cutaneous Leishmania (Viannia) braziliensis infection with liposomal amphotericin B Infect Dis Clin Pract 13 2005 84 86
21. A.M. Rodrigues, M. Hueb, T.A. Santos, and C.J. Fontes [Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate] Rev Soc Bras Med Trop 39 2006 139 145